Arnold Robert W, Gionet Elisha, Hickel Jason, Owen Michael, Armitage M Diane
Ophthalmic Associates, Pediatric Ophthalmology and Strabismus, Anchorage, Alaska 99501-2242, USA.
Binocul Vis Strabismus Q. 2004;19(2):81-6.
Atropine dilates the pupil and paralyzes the ciliary muscle accommodation, blurring vision, and therefore is an effective penalization of the sound eye in the treatment of functional amblyopia of the other eye. The degree of blur induced is a function of the amount of the patient's uncorrected hyperopia and the distance from the eye of the viewed material or object. Another factor determining effectiveness of atropine penalization is the duration of the effect of the atropine. It is the purpose of this study to investigate these factors.
Six normal children underwent complete eye exam with cycloplegic refraction several days before deliberate instillation of atropine 1% in the sound, or right eye. Distance and near acuity was then tested after 30 minutes, and on subsequent days. Additional data points were derived by placing known minus lenses in front of the tested eye. In addition, we also studied one successfully treated amblyopic patient when he terminated chronic daily atropine in his normal, sound eye.
Atropine initially produced a linear reduction in logMAR acuity (blur) at distance of about 0.2 logMAR lines per diopters of uncorrected hyperopia. The magnitude of the blur was greater for near, but the effect of increased hyperopia was slightly greater for distance measurements. This blurring of acuity lasted just less than 48 hours for normal subjects, and just over 48 hours following prompt cessation of chronic daily atropine in that one subject. Regression formulae were derived relating uncorrected hyperopia and time interval following atropine cessation on distance and near acuity in children of amblyopic age range.
The degree of penalization is highly dependent on the uncorrected hyperopic refractive error. A significant penalization effect is present only for one day or so. Daily atropine is therefore indicated for penalization. To better tailor penalization therapy to target sound eye acuity blur, these formulae and graphs can be used, specifically, in addition, to determine the amount of deliberate spectacle hyperopic undercorrection to maximize the penalization effect.
阿托品可使瞳孔散大并使睫状肌调节麻痹,导致视力模糊,因此在治疗另一只眼的功能性弱视时,它是一种有效的健眼抑制方法。所诱发的模糊程度取决于患者未矫正远视的度数以及被观察材料或物体与眼睛的距离。决定阿托品抑制效果的另一个因素是阿托品的作用持续时间。本研究旨在探讨这些因素。
6名正常儿童在有意向健眼(右眼)滴入1%阿托品数天前,进行了散瞳验光的全面眼部检查。然后在30分钟后及随后几天测试远视力和近视力。通过在被测试眼前放置已知度数的负透镜获得额外的数据点。此外,我们还研究了一名成功治疗的弱视患者,当他停止在其正常健眼每日使用阿托品时的情况。
阿托品最初使远视力的logMAR视力(模糊程度)呈线性下降,每屈光度未矫正远视约下降0.2 logMAR行。近视力的模糊程度更大,但远视增加对远视力测量的影响略大。正常受试者的这种视力模糊持续时间略少于48小时,而在该名受试者停止每日使用阿托品后,这种模糊持续时间略超过48小时。得出了关于未矫正远视与弱视年龄范围儿童停止使用阿托品后的时间间隔对远视力和近视力影响的回归公式。
抑制程度高度依赖于未矫正的远视屈光不正。显著的抑制效果仅持续一天左右。因此,每日使用阿托品适用于抑制治疗。为了更好地根据目标健眼视力模糊调整抑制治疗,这些公式和图表可用于,具体而言,此外,还可用于确定有意进行的远视眼镜欠矫量,以最大化抑制效果。